Calamos Advisors
RVMD icon

Calamos Advisors’s Revolution Medicines RVMD Stock Holding History

Calamos Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.91M Buy
23,944
+4,233
+21% +$839K 0.01% 561
2026
Q2 		$3.69M Buy
19,711
+4,248
+27% +$620K 0.01% 591
2026
Q1 		$1.5M Buy
15,463
+3,003
+24% +$303K 0.01% 711
2025
Q4 		$992K Buy
+12,460
New +$817K ﹤0.01% 696

Other funds holding RVMD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Calamos Advisors's RVMD Position: Q3 2026 in Review

Calamos Advisors increased its Revolution Medicines (RVMD) stake by 21% in Q3 2026, buying an estimated $839K and bringing the position to 23,944 shares worth $4.91M. The position accounts for 0.01% of the portfolio, ranked #561.

Calamos Advisors first reported a position in RVMD in Q4 2025 and has held it in 4 quarters since. 329 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Calamos Advisors held 23,944 shares of Revolution Medicines worth $4.91M as of Q3 2026.
  • Calamos Advisors bought 4,233 Revolution Medicines shares in Q3 2026, an estimated $839K.
  • Revolution Medicines made up 0.01% of Calamos Advisors's portfolio in Q3 2026, its #561 holding.
  • Calamos Advisors first reported a position in Revolution Medicines in Q4 2025 and has held it in 4 quarters since.
  • 329 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Calamos Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.